Segmental Analysis
Global Generics
Revenues from Global Generics segment are at ?16.1 billion
Does not say much about fonda
http://www.drreddys.com/media/popups/oct25_2011_q2fy12.html
($329 million) in Q2 FY12 registering growth of 18% over previous year.
Revenues from North America at ?6.3 billion in Q2 FY12 versus ?4.4 billion in Q2 FY11. Growth in USD terms of 45% was led by new product launches in the last twelve months and market share improvement in key products.
5 new products launched during the quarter, including limited competition products such as fondaparinux and fexofenadine pseudoephedrine D24 OTC.
24 products of our prescription portfolio feature among the Top 3 rank in market share (Source: IMS Sales Volumes July 2011).
During the quarter, 4 ANDAs were filed. The cumulative ANDA filings as of 30th September, 2011 are 177. A total of 76 ANDAs are pending for approval with the USFDA of which 40 are Para IVs and 11 are FTFs.
- Forums
- ASX - By Stock
- dr reddys quarterly -- does not say much
Segmental AnalysisGlobal GenericsRevenues from Global Generics...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable